The predictivity of preliminary embryo-fetal development (EFD) studies : results of a retrospective survey in Japanese pharmaceutical companies
スポンサーリンク
概要
- 論文の詳細を見る
To explore the predictivity of dose range-finding (DRF) studies, we conducted asurvey by sending out questionnaires to 72 Japanese pharmaceutical companies.The survey yielded data for 108 and 85 compounds for which any embryo-fetaldevelopment (EFD) toxicities were observed in the definitive studies in rodentsand non-rodents, respectively. As a result of the analysis, 83% of studies inrodents and 80% in non-rodents showed EFD effects in the DRF studies. Whenfocusing on teratogenicity, 91% of studies in rodents and 100% in non-rodentswere judged “positive” in the DRF studies when all EFD toxicities were used asmarkers. When the effects of both the rodent and non-rodent studies wereevaluated together, the combination predictive value in the DRF studies was 96%for EFD toxicants and 100% for teratogens. To evaluate the influence of theexamination items, the predictive value was analyzed using 54 compounds forwhich full examinations (external, visceral and skeletal examination) wereconducted in both rodent and non-rodent DRF studies. When the results werejudged by including or excluding skeletal and visceral examinations results,the predictive values were not significantly different. In conclusion, theresults of this survey showed that a pair of the DRF studies in the rodents andnon-rodents is useful to increase the predictivity of DRF studies. In additionthe inclusion of observations such as fetal survival, body weight and externalexamination into the DRF studies are important to predict effects in thedefinitive studies.
- 2010-02-01
著者
-
OKAHASHI Noriko
Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures A
-
IKEDA Takashi
Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures A
-
KAI Shuichi
Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures A
-
KOMATSU Shinichi
Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures A
-
MATSUI Hajime
Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures A
-
YAMASHITA Yasuhiro
Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures A
-
YAMAMOTO Keiji
Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures A
-
SAGAMI Fumio
Non-clinical Evaluation Subcommittee, Drug Evaluation Committee, Japan Pharmaceutical Manufactures A
-
Matsui Hajime
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufactures Ass
-
Okahashi Noriko
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufactures Ass
-
Okahashi Noriko
住友化学工業
-
Kai Shuichi
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufacturers As
-
Kai Shuichi
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufactures Ass
-
Sagami Fumio
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufacturers As
-
Sagami Fumio
Drug Safety Research Laboratories Eisai Co. Ltd.
-
Komatsu Shinichi
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufactures Ass
-
Yamamoto Keiji
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufactures Ass
-
Yamashita Yasuhiro
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufactures Ass
-
Komatsu Shinichi
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufactures Ass
-
Sagami Fumio
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufactures Ass
-
Ikeda Takashi
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufactures Ass
-
Yamamoto Keiji
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufactures Ass
-
Yamamoto Keiji
Non-clinical Evaluation Subcommittee Drug Evaluation Committee Japan Pharmaceutical Manufactures Ass
関連論文
- The predictivity of preliminary embryo-fetal development (EFD) studies : results of a retrospective survey in Japanese pharmaceutical companies
- Collaborative work on evaluation of ovarian toxicity by repeated-dose and fertility studies in female rats
- P8-20 QT Interval Prolongation : Project for Database Construction, 14) Safety Margins of Drug-Induced QT Interval Prolongation: Comparison of Non-Clinical Animal Models and Clinical Data(CIRCULATORY SYSTEM-2/ACTIVE OXYGEN)(GENERAL SESSION BY POSTER PRESE
- QT PRODACT : Sensitivity and Specificity of the Canine Telemetry Assay for Detecting Drug-Induced QT Interval Prolongation
- Safety assessment of biopharmaceuticals : Japanese perspective on ICH S6 guideline maintenance
- Points to consider on the non-clinical safety evaluation of anticancer drugs
- CURRENT OPINION : SAFETY EVALUATION OF DRUG METABOLITES IN DEVELOPMENT OF PHARMACEUTICALS
- "POINTS TO CONSIDER" REGARDING SAFETY ASSESSMENT OF BIOTECHNOLOGY-DERIVED PHARMACEUTICALS IN NON-CLINICAL STUDIES (ENGLISH TRANSLATION)
- Current status of pharmaceutical industries in Japan on pharmacogenomics and toxicogenomics in 2005(Toxicogenomics, Toxicoproteomics, Proceedings of the 32nd Annual Meeting)
- S3-6 Problems and Meanings of Genome-based Drug Discovery in Japanese Pharmaceutical Companies(SYMPOSIUM 3: BENEFITS OF PHARMACOGENOMICS/PHARMACOGENETICS IN PHARMACEUTICAL DEVELOPMENT)(Proceedings of the 31st Annual Meeting)
- P8-02 Effects of E-4031 and Verapamil on electrocardiogram and blood pressure in dogs and Monkeys(CIRCULATORY SYSTEM-2/ACTIVE OXYGEN)(GENERAL SESSION BY POSTER PRESENTATION)(Proceedings of the 31st Annual Meeting)
- Questionnaire survey on cardiac electrophysiology examination in safety pharmacology studies.(GENERAL SESSION BY POSTER PRESENTATION)(SAFETY PHARMACOLOGY)
- P8-49 Questionnaire Survey of GLP Operation for S7A Safety Pharmacology Study in Japanese and Foreign CROs(BLOOD/TOXICOKINETICS/OTHERS-2)(GENERAL SESSION BY POSTER PRESENTATION)(Proceedings of the 31st Annual Meeting)
- QT PRODACT : Comparison of Non-clinical Studies for Drug-Induced Delay in Ventricular Repolarization and Their Role in Safety Evaluation in Humans
- QT PRODACT : In Vivo QT Assay With a Conscious Monkey for Assessment of the Potential for Drug-Induced QT Interval Prolongation
- QT PRODACT : In Vivo QT Assay in Anesthetized Dog for Detecting the Potential for QT Interval Prolongation by Human Pharmaceuticals
- QT PRODACT : In Vivo QT Assay in the Conscious Dog for Assessing the Potential for QT Interval Prolongation by Human Pharmaceuticals
- QT PRODACT : Evaluation of the Potential of Compounds to Cause QT Interval Prolongation by Action Potential Assays Using Guinea-Pig Papillary Muscles
- QT PRODACT : Inter- and Intra-facility Variability of the Action Potential Assay Using Isolated Guinea-Pig Papillary Muscles
- QT PRODACT : A Multi-site Study of In Vitro Action Potential Assays on 21 Compounds in Isolated Guinea-Pig Papillary Muscles
- P8-19 QT Interval Prolongation : Project for Database Construction, 13) Species-Difference in Dose-Response Relationship of Drug-Induced QT Interval Prolongation(CIRCULATORY SYSTEM-2/ACTIVE OXYGEN)(GENERAL SESSION BY POSTER PRESENTATION)(Proceedings of th
- P8-18 QT Interval Prolongation : Project for Database Construction, 12) QT prolongation: Comparison of the sensitivity between canine telemetry assay and isoflurane-anesthetized model(CIRCULATORY SYSTEM-2/ACTIVE OXYGEN)(GENERAL SESSION BY POSTER PRESENTAT
- P8-17 QT Interval Prolongation : Project for Database Construction, 11) Evaluation of the drug-induced QT interval change using the individual QT-RR interval relationship in telemetered dogs(CIRCULATORY SYSTEM-2/ACTIVE OXYGEN)(GENERAL SESSION BY POSTER PR
- P8-16 QT Interval Prolongation : Project for Database Construction, 10) Sensitivity to detect drug-induced changes in QT interval for monkey telemetry assay with individual QT-RR correction(CIRCULATORY SYSTEM-2/ACTIVE OXYGEN)(GENERAL SESSION BY POSTER PRE
- P8-15 QT prolongation : Project for Database Construction, 9) Individual QT-RR correction and sensitivity to detect drug-induced changes in QT interval for canine telemetry assay(CIRCULATORY SYSTEM-2/ACTIVE OXYGEN)(GENERAL SESSION BY POSTER PRESENTATION)(
- P8-14 QT Interval Prolongation : Project for Database Construction, 8) Dose (concentration) response analysis of drug-induced QT interval prolongation in anesthetized dogs(CIRCULATORY SYSTEM-2/ACTIVE OXYGEN)(GENERAL SESSION BY POSTER PRESENTATION)(Proceed
- P8-13 QT interval prolongation : Project for Database Construction, 7) Dose (concentration)-response analysis of drug-induced QT interval prolongation in conscious monkeys(CIRCULATORY SYSTEM-2/ACTIVE OXYGEN)(GENERAL SESSION BY POSTER PRESENTATION)(Proceed
- P8-12 QT Interval Prolongation : Project for Database Construction, 6) Dose (concentration)-response analysis of drug-induced QT interval prolongation in conscious dogs(CIRCULATORY SYSTEM-2/ACTIVE OXYGEN)(GENERAL SESSION BY POSTER PRESENTATION)(Proceeding
- P8-11 QT Interval Prolongation : Project for Database Construction, 5) Standard protocol and inter-facility differences in electrocardiographic determination in anesthetized dogs(CIRCULATORY SYSTEM-2/ACTIVE OXYGEN)(GENERAL SESSION BY POSTER PRESENTATION)(
- P8-10 QT Interval Prolongation : Project for Database Construction, 4) Inter-facility Differences in Electrocardiographic and Hemodynamic Parameters in Telemetered Monkeys(CIRCULATORY SYSTEM-2/ACTIVE OXYGEN)(GENERAL SESSION BY POSTER PRESENTATION)(Proceed
- P8-09 QT Interval Prolongation : Project for Database Construction, 3) Inter-facility Differences in Electrocardiograhic and Hemodynamic Parameters in Telemetered Dogs(CIRCULATORY SYSTEM-2/ACTIVE OXYGEN)(GENERAL SESSION BY POSTER PRESENTATION)(Proceedings
- O-09 No-Observed Adverse Effect Level(NOAEL) : Judging Criteria and Purpose in Safety Assessment of Pharmaceuticals(STATISTICAL AND TEST METHODS/GENERAL TOXICITY)(GENERAL SESSION BY ORAL PRESENTATION)(Proceedings of the 31st Annual Meeting)
- O-08 Questionnaire Survey on No Observed Adverse Effect Level(2) : Regulatory Comments and Company(STATISTICAL AND TEST METHODS/GENERAL TOXICITY)(GENERAL SESSION BY ORAL PRESENTATION)(Proceedings of the 31st Annual Meeting)
- O-07 Questionnaire Survey on No Observed Adverse Effect Level(1) : Concept of NOAEL(STATISTICAL AND TEST METHODS/GENERAL TOXICITY)(GENERAL SESSION BY ORAL PRESENTATION)(Proceedings of the 31st Annual Meeting)
- Survey of pharmacology study conduct using outside sources in pharmaceutical companies in Japan.(GENERAL SESSION BY ORAL PRESENTATION)(MINI SYMPOSIUM : CONSIDERATION OF OUTSOURCINGS AND MONITORING IN NON-CLINICAL STUDY(CURRENT SURVEY))
- Study Monitor : The Surveillance of Outsourced Non-Clinical Studies : Draft Report, Final Report, Archives, and Quality Assurance(GENERAL SESSION BY ORAL PRESENTATION)(MINI SYMPOSIUM : CONSIDERATION OF OUTSOURCINGS AND MONITORING IN NON-CLINICAL STUDY(CUR
- Study monitor : the Surveillance of Outsourced Non-Clinical Studies (Reproductive Studies,Pathology and Toxicokinetics).(GENERAL SESSION BY ORAL PRESENTATION)(MINI SYMPOSIUM : CONSIDERATION OF OUTSOURCINGS AND MONITORING IN NON-CLINICAL STUDY(CURRENT SURV
- Study Monitor. The Surveillance of Outsourced Non-Clinical Studies : Testing facility checking, Protocol, Formulation and In-life phase(GENERAL SESSION BY ORAL PRESENTATION)(MINI SYMPOSIUM : CONSIDERATION OF OUTSOURCINGS AND MONITORING IN NON-CLINICAL STU
- Study Monitor. Introduction of the Surveillance for Outsourcing Non-Clinical Studies and Summary of Toxicology.(GENERAL SESSION BY ORAL PRESENTATION)(MINI SYMPOSIUM : CONSIDERATION OF OUTSOURCINGS AND MONITORING IN NON-CLINICAL STUDY(CURRENT SURVEY))
- P8-07 QT Interval Prolongation : Project for Database Construction, 1) Standard Protocol, and Inter- and Intra-Facility Differences in APD Assay Using Isolated Guinea Pig Papillary Muscles(CIRCULATORY SYSTEM-2/ACTIVE OXYGEN)(GENERAL SESSION BY POSTER PRES
- STUDIES ON EXPERIMENTAL IODINE ALLERGY : 3. LOW MOLECULAR WEIGHT ELICITOGENIC ANTIGENS OF IODINE ALLERGY
- STUDIES ON EXPERIMENTAL IODINE ALLERGY : 2. IODINATED PROTEIN ANTIGENS AND THEIR GENERATION FROM INORGANIC AND ORGANIC IODINE-CONTAINING CHEMICALS
- STUDIES ON EXPERIMENTAL IODINE ALLERGY : 1. ANTIGEN RECOGNITION OF GUINEA PIG ANTI-IODINE ANTIBODY
- COMPARISON OF SPERM MOTILITY TEST METHODS(EXCEPT COMPUTER-ASSISTED SPERM ANALYSIS)IN RATS UNDER THE CONDITION OF ALFA-CHLOROHYDRIN TREATMENT : COLLABORATIVE INVESTIGATION
- P-11 Application of hepatocytes cultured in a sandwich configuration to toxicity assessment.(Proceedings of the 27th Annual Meeting)
- P8-08 QT Interval Prolongation : Project for Database Construction, 2) The Usefulness of APD Study in Isolated Guinea Pig Papillary Muscles-Comparison with hERG study and canine Purkinje fiber APD study(CIRCULATORY SYSTEM-2/ACTIVE OXYGEN)(GENERAL SESSION
- Mechanism for benzothiazole derivative-induced hepatotoxicity in rats(SYMPOSIUM 1 : MECHANISMS OF HEPATOTOXIC EFFECTS)
- P-90 Collaborative Work to Evaluate Toxicity on Male Reproductive Organs with 2 Weeks Repeated Daily Dosing in Rats : Testicular Toxicity of E7010, A Sulfonamide Tubulin Polymerlzation Inhibitor(Proceedings of the 27th Annual Meeting)
- COLLABORATIVE WORK TO EVALUATE TOXICITY ON MALE REPRODUCTIVE ORGANS BY REPEATED DOSE STUDIES IN RATS : 17)TESTICULAR TOXICITY OF E7010, A SULFONAMIDE TUBULIN POLYMERIZATION INHIBITOR
- TOXICOLOGICAL RESPONSE OF RATS TO A NOVEL MONOAMINE OXIDASE TYPE-A INHIBITOR, (5R)-3-[2-((1S)-3-CYANO-1-HYDROX-YPROPYL)BENZOTHIAZOL-6-YL]-5-METHOXYMETHYL-2-OXAZOLIDI-NONE (E2011), ORALLY ADMINISTERED FOR 13 WEEKS
- "B-5 Modification of Drug Conjugation Pathway by Repeated Administration of Conjugating Enzyme Inhibitors in Rats.
- QT PRODACT : Inter-facility Variability in Electrocardiographic and Hemodynamic Parameters in Conscious Dogs and Monkeys
- DETERMINATION OF THE TIME AT WHICH CONGENITAL HYDROCEPHALUS IS INDUCED WITH HIGHER INCIDENCE DURING THE EARLY GESTATIONAL PERIOD IN RATS